NASDAQ: PBYIPuma Biotechnology Inc Stock
$5.13-0.04 (-0.77%)
Updated Apr 23, 2024
PBYI Price
$5.13
Fair Value Price
-$0.19
Market Cap
$247.30M
52 Week Low
$2.13
52 Week High
$7.73
P/E
11.15x
P/B
4.63x
P/S
0.87x
PEG
0.39x
Dividend Yield
N/A
Revenue
$235.64M
Earnings
$21.59M
Gross Margin
73.4%
Operating Margin
15.28%
Profit Margin
9.2%
Debt to Equity
3.31
Operating Cash Flow
$27M
Beta
1.13
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PBYI Overview
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PBYI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PBYI ($5.13) is overvalued by 2,783.85% relative to our estimate of its Fair Value price of -$0.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PBYI ($5.13) is not significantly undervalued (2,783.85%) relative to our estimate of its Fair Value price of -$0.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PBYI ($5.13) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PBYI due diligence checks available for Premium users.
Be the first to know about important PBYI news, forecast changes, insider trades & much more!
PBYI News
Valuation
PBYI fair value
Fair Value of PBYI stock based on Discounted Cash Flow (DCF)
Price
$5.13
Fair Value
-$0.19
Undervalued by
2,783.85%
PBYI ($5.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PBYI ($5.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PBYI ($5.13) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PBYI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
11.15x
Industry
16.46x
Market
41.92x
PBYI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PBYI is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PBYI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.63x
Industry
5.93x
PBYI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PBYI price to earnings growth (PEG)
For valuing profitable companies with growth potential
PBYI is good value based... subscribe to Premium to read more.
PEG Value Valuation
PBYI's financial health
Profit margin
Revenue
$72.2M
Net Income
$12.3M
Profit Margin
17%
PBYI's Earnings (EBIT) of $36.00M... subscribe to Premium to read more.
Interest Coverage Financials
PBYI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$230.5M
Liabilities
$177.1M
Debt to equity
3.31
PBYI's short-term assets ($156.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBYI's short-term assets ($156.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBYI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PBYI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$10.5M
Investing
-$8.2M
Financing
$0.0
PBYI's operating cash flow ($27.01M)... subscribe to Premium to read more.
Debt Coverage Financials
PBYI vs Biotech Stocks
Puma Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.